When cells are Harvard Medical School challenged with apoptotic stimuli, death-promoting Boston, Massachusetts 02115 Bcl-2 family members become activated, and the equi- † D-47G/AP10-LL/Nuclear Magnetic Resonance librium within the Bcl-2 family protein network shifts Research toward apoptosis. Apoptosis then occurs through a cas-Abbott Laboratories cade of events that culminates in the release of cyto-100 Abbott Park Road chrome c from the mitochondria and subsequent death Abbott Park, Illinois 60064 protease activation (Reed, 1998). ‡ Division of Signal Transduction A subset of the proapoptotic Bcl-2 family proteins are Department of Medicine and localized to the cytoplasm under conditions of cellular Department of Surgery survival and translocate to the mitochondria under apo-Beth Israel Deaconess Medical Center ptotic conditions, making these Bcl-2 family members Boston, Massachusetts 02215 attractive candidates for molecular switches that regulate cell death in response to changes in the extracellular environment (Zha et al., 1996; Li et al., 1998; Luo et al., Summary 1998). One proapoptotic molecule that belongs to this subset of the Bcl-2 family is BAD (Yang et al., 1995; The Bcl-2 homology 3 (BH3) domain of prodeath Bcl-2 reviewed in Datta et al., 1999). Structural and functional family members mediates their interaction with proanalysis indicates that a key role of survival factors is survival Bcl-2 family members and promotes apoto inhibit the activity of BAD. In the absence of survival ptosis. We report that survival factors trigger the phosstimuli, endogenous BAD is dephosphorylated and lophorylation of the proapoptotic Bcl-2 family member calized to the outer mitochondrial membrane where BAD BAD at a site (Ser-155) within the BAD BH3 domain. binds to prosurvival Bcl-2 family members via its Bcl-2 When BAD is bound to prosurvival Bcl-2 family memhomology 3 (BH3) domain, an amphipathic ␣ helix that bers, BAD Ser-155 phosphorylation requires the prior is conserved in all proapoptotic Bcl-2 family members phosphorylation of Ser-136, which recruits 14-3-3 proand is critical to the death-promoting function of these teins that then function to increase the accessibility of proteins. Survival factors, acting through kinases such Ser-155 to survival-promoting kinases. Ser-155 phosas Akt and PKA, induce endogenous BAD phosphorylaphorylation disrupts the binding of BAD to prosurvival tion at two evolutionarily conserved sites, Ser-112 and Bcl-2 proteins and thereby promotes cell survival. These Ser-136, which leads to the translocation of BAD from findings define a mechanism by which survival signals the mitochondria to the cytoplasm and the inhibition of inactivate a proapoptotic Bcl-2 family member, and BAD-dependent death (reviewed in Datta et al., 1999). suggest a role for 14-3-3 proteins as cofactors that It has been proposed that the phosphorylation of BAD regulate sequential protein phosphorylation events. at Ser-112 and/or Ser-136 induces a conformational change in BAD that blocks its ability to interact with Introduction prosurvival Bcl-2 family members such as BCL-X L (Wang et al., 1999). Secondary structural prediction models Survival factors, acting through their cognate cell sursuggest that BAD Ser-112 lies within an N-terminal ␣ face receptors, activate intracellular signaling cascades helix, while Ser-136 lies within an adjacent unstructured that promote survival by suppressing an intrinsic cellular loop domain. However, deletion analysis and mutagenedeath program (Vaux and Korsmeyer, 1999). Proteins of sis have revealed that the ability of BAD to regulate the Bcl-2 family are components of a survival factorapoptosis is conferred exclusively by its C-terminal BH3 regulated checkpoint in the cellular death machinery domain (Kelekar et al., 1997; Ottilie et al., 1997; Zha et (Reed, 1998). Bcl-2 family members promote either sural., 1997). Although phosphorylation of Ser-112 and Servival (e.g., BCL-2, BCL-X L , and the C. elegans Bcl-2 136 is critical for inactivating BAD, it is not clear how homolog CED-9) or apoptosis (e.g., BAK, BAD, and the phosphorylation of the BAD N terminus effects a change C. elegans BCL-2 homolog EGL-1). Although the precise in the activity of the distal BAD BH3 domain and leads mechanism by which the Bcl-2 proteins function reto the disruption of the BAD/BCL-X L complex. mains unclear, their ability to homo-and heterodimerize Phosphorylation of BAD at Ser-112 and Ser-136 prohas given rise to the hypothesis that the balance bemotes the interaction of BAD with 14-3-3 proteins, a tween prosurvival and prodeath Bcl-2 family members large family of proteins that bind to phosphoserine and phosphothreonine-containing ligands and are thought to act as molecular chaperones (Muslin et al., 1996; Yaffe § To whom correspondence should be addressed (e-mail: greenberg@ hub.tch.harvard.edu). et al., 1997). The binding of BAD to 14-3-3 correlates with
BAD inactivation, and 14-3-3 proteins promote cellular
In addition, these findings suggest a new role for 14-3-3 survival, consistent with a causative role for 14-3-3 proproteins as cofactors that cooperate with kinases to teins in blocking the ability of BAD to induce cell death promote sequential phosphorylation events. (Hsu et al., 1997; Xing et al., 2000) . However, it is not known whether 14-3-3 binding to phosphorylated BAD Results is sufficient to displace BAD from BCL-X L or is sufficient to inactivate the proapoptotic activity of BAD.
By interrogating the BAD primary sequence for consen-Here we show that survival signals block apoptosis by sus phosphorylation motifs that are potential targets for phosphorylating the proapoptotic Bcl-2 family member protein kinases that promote cell survival, we identified BAD at Ser-155, a site within its BH3 domain. In the a phosphorylation site for PKA (RRXS) within the BAD absence of survival stimuli, BAD is dephosphorylated BH3 domain ( Figure 1A) (Songyang et al., 1994) . Seand bound to BCL-X L . Upon exposure to survival factors, quence alignment of BAD from species ranging from Ser-136 phosphorylation is induced, leading to the rehuman to zebrafish reveals that this site (Serine-155 in cruitment of 14-3-3 proteins to BAD. We find that 14-3-3 mouse) is evolutionarily conserved, suggesting that Seronly weakly binds to the BAD/BCL-X L complex but effec-155 phosphorylation may regulate BAD function. Modeltively increases the accessibility of Ser-155 to survival ing of the BAD/BCL-X L interaction based upon a prekinases. Phosphorylation of BAD Ser-155 disrupts the viously derived NMR structure of the BAK BH3 domain interaction between the hydrophobic face of the BAD complexed to BCL-X L (Sattler et al., 1997) indicated that BH3 domain and the hydrophobic groove in BCL-X L , Ser-155 of BAD points toward the hydrophobic cleft of causing BAD to dissociate from BCL-X L . BAD then trans-BCL-X L ( Figure 1B) . Phosphorylation of BAD Ser-155 is locates from the outer mitochondrial membrane to the therefore predicted to interfere with the ability of BAD to cytoplasm, where it forms a stable complex with 14-3-3 bind to BCL-X L due to the addition of a bulky, negatively proteins. These observations identify Ser-155 as a site charged phosphate group to the sterically constrained whose phosphorylation is critical for cellular survival, hydrophobic interaction interface between BAD and and raise the possibility that BH3 domain phosphoryla-BCL-X L . A recently generated solution structure of the tion may be a general mechanism by which survival factors inactivate proapoptotic Bcl-2 family members. BAD BH3 domain complexed to BCL-X L verifies this prediction (S. W. F., unpublished data). We hypothesized that because Ser-155 is embedded within an evolutionarily conserved PKA phosphorylation site and is well positioned within the BH3 domain to regulate the BAD/ BCL-X L interaction, BAD Ser-155 may serve as a critical site of phosphorylation by protein kinases that promote cell survival.
Phosphorylation of BAD Ser-155 In Vitro and In Vivo
To test whether PKA functions as a BAD Ser-155 kinase, we assessed the ability of purified PKA to phosphorylate recombinant BAD in vitro. We generated mutant forms of recombinant BAD in which serines 112, 136, and 155, either singly or in combination, were converted to alanine so that BAD could no longer be phosphorylated at these sites. Wild-type and mutant forms of BAD were incubated with PKA and [␥Ϫ 32 P]ATP, and the reaction products were analyzed by SDS-PAGE followed by autoradiography. As shown in Figure 1C , PKA phosphorylates wild-type BAD protein, as well as BAD protein with Ser-112 mutated to alanine (S112A), Ser-136 mutated to alanine (S136A), or both sites mutated to alanine binding. Two hundred nanograms of recombinant WT or mutant BAD was either prephosphorylated with .25 U PKA or mock incubated at 30Њ for 30 min. GST-BCL-X L beads were then incubated for 1 hr in 1% NP40 lysis buffer with the BAD proteins. After incubation, the supernatants and pellets were separately isolated and slot blotted with anti-BAD or anti-BAD155 pAbs. (B) Mutation of BAD Ser-155 to aspartic acid disrupts the ability of BAD to bind to BCL-X L in cells. HEK 293 cells were transfected with expression vectors encoding BCL-X L and either WT BAD or the BAD S155D mutant. Thirty-six hours after transfection, cells were lysed in .2% NP40 lysis buffer, and the whole-cell lysates, anti-BAD immunoprecipitates, and immunoprecipitation supernatants were separately isolated and subjected to SDS-PAGE and Western blotting with the antibodies indicated. (C) The 14-3-3/BAD interaction depends on Ser-136 phosphorylation, and not Ser-155 phosphorylation in cells. HEK 293 cells were transfected with expression constructs encoding 14-3-3 and either WT BAD, the BAD alanine phosphorylation site mutants, or BADS155D. Cells were lysed and immunoprecipitated as in (B), except that 1% NP40 lysis buffer was used for lysis and washing, and anti-BAD was used as the immunoprecipitating antibody. Lysates, supernatants, and immunoprecipitates were analyzed by Western blotting with the antibodies indicated.
growth factor (PDGF). Western blotting of lysates de-BAD Ser-155 Phosphorylation Disrupts BCL-X L Binding rived from these cells revealed that both PKA agonists and PDGF induced the phosphorylation of BAD at Ser-Given the location of Ser-155 within the BAD BH3 domain, we investigated whether Ser-155 phosphorylation 155 (Figure 2B). Both dbcAMP/IBMX and PDGF induced a shift in the migration of BAD on SDS-PAGE, suggesting
disrupts the ability of BAD to bind BCL-X L . GST-BCL-X L protein coupled to glutathione beads was used as an that these stimuli induced the phosphorylation of BAD at both Ser-112 and Ser-136. As shown in Figure 2C , affinity reagent to precipitate recombinant BAD, and the ability of BAD phosphorylation to influence the BCL-X L / PKA agonists and IGF-1 also induced the phosphorylation of BAD at Ser-155 in cerebellar granule neurons, BAD interaction was assessed. Wild-type BAD and the various BAD phosphorylation site mutants (BAD2SA, and treatment of these cells simultaneously with PKA agonists and IGF-1 promoted enhanced BAD Ser-155 BADS155A, and BAD3SA, a derivative in which all three phosphorylation sites were mutated to alanine) inter-phosphorylation ( Figure 2D ). Taken together, these findings demonstrate that endogenous BAD is inducibly acted with BCL-X L in the absence of PKA ( Figure 3A) . However, when BAD and the BAD derivatives were pre-phosphorylated at Ser-155 in multiple cell types in response to survival stimuli, including PKA agonists and incubated with PKA, those BAD variants that had an intact Ser-155 phosphorylation site no longer interacted growth factors.
Wild-type and S155A peptides bound to BCL-X L with extremely high affinity, with dissociation constants of .4 nmol and .1 nmol, respectively (see Experimental Procedures). In contrast, a BAD BH3 peptide that was synthesized with a phosphoserine in the place of Ser-155 bound to BCL-X L with a dissociation constant of 8100 nmol, indicating that phosphorylation of BAD at Ser-155 effectively disrupts the binding of BAD to BCL-X L in vitro.
We next asked if Ser-155 phosphorylation disrupted the BAD/BCL-X L interaction in vivo. As it is difficult to obtain stoichiometric phosphorylation of a single site in cells, we generated a derivative of BAD in which Ser-155 was mutated to aspartic acid (S155D), an acidic amino acid whose negative charge may mimic the effects of phosphorylation. Fluorescence anisotropy experiments verified that this mutation effectively abrogated the binding of the BAD BH3 domain to BCL-X L . WT BAD and BADS155D were expressed in 293 cells, and their ability to interact with coexpressed BCL-X L was assessed by Western blotting. As shown in Figure  3B , WT BAD coimmunoprecipitated with BCL-X L . In addition, BAD with any or all of the phosphorylation sites mutated to alanine coimmunoprecipitated with BCL-X L (data not shown). However, mutation of Ser-155 to aspartic acid completely blocked the ability of BAD to coimmunoprecipitate with BCL-X L , suggesting that phosphorylation at Ser-155 disrupts the BCL-X L /BAD interaction within cells ( Figure 3B ). Because endogenous kinases phosphorylate a fraction of expressed BAD in 293 cells at multiple sites including Ser-155, we asked whether the Ser-155-phosphorylated form of BAD interacts with BCL-X L in cells. BAD that coimmunoprecipi- shown, Figure 3C ), suggesting that Ser-112 or Ser-155 phosphorylation is not required for the BAD/14-3-3 interaction. In addition, Western blotting the 14-3-3 immunowith BCL-X L , whereas the BAD mutants in which Serprecipitates with anti-BAD155 pAbs revealed that 14-3-3 155 was converted to an alanine still interacted with interacts with BAD that is phosphorylated at Ser-155 in BCL-X L . In addition, blotting the GST-BCL-X L beads and vivo. These results suggest that Ser-155 phosphorylathe supernatants with anti-BAD155 pAbs revealed that tion disrupts the interaction of BAD with BCL-X L but none of the BAD that precipitated with GST-BCL-X L was does not significantly affect the ability of BAD to interact phosphorylated at Ser-155. Instead, BAD phosphorywith 14-3-3 proteins. Figure 5B) . We asked whether the defect in phosphorylation site mutants to induce apoptosis in culcell death induced by acidic substitution of BAD Sertured cerebellar granule neurons. For this analysis, we 112 and Ser-136 required the phosphorylation of BAD cotransfected various BAD alleles into the neurons toat Ser-155 by transfecting cells with a BADS112D/S136D gether with a plasmid expressing the reporter ␤ galacderivative in which Ser-155 was mutated to alanine. In tosidase to facilitate the identification of transfected contrast to BADS112D/S136D, the BADS112D/S136D/ cells, and scored transfected cells in a blinded manner S155A mutant was not impaired in its ability to promote based on nuclear morphology. The mechanism by which BAD Ser-136 phosphorylation leads to Ser-155 phosphorylation was next investigated. ptosis, the BADS155D construct did not promote apoptosis above the level observed in vector-transfected We hypothesized, based upon transfection experiments in a number of cell lines (data not shown), that Ser-155 cells that were deprived of trophic support for 24 hr (Figure 5C ). To address whether phosphorylation of BAD phosphorylation may require Ser-136 phosphorylation only when BAD is bound to BCL-X L . The necessity for Ser-155 inactivates BAD even when BAD Ser-136 is not phosphorylated, we generated a mutant BAD allele in additional events, such as Ser-136 phosphorylation, to induce Ser-155 phosphorylation was suggested by the which Ser-112 and Ser-136 were converted to alanine, but Ser-155 was converted to aspartic acid. As shown molecular modeling of the BCL-X L /BAD complex ( Figure  1A) , which revealed that when BAD is bound to BCL-X L , in Figure 5C , mutation of BAD Ser-155 to aspartate completely abrogated the ability of BAD to promote cell Ser-155 is buried in the BCL-X L /BAD interface and is likely inaccessible to kinases. To verify this conclusion death even when Ser-112 and Ser-136 were converted to alanine. Taken together, these data suggest that Ser-experimentally, glutathione-coupled BCL-X L /BAD complexes were isolated and subsequently incubated with 136 phosphorylation inhibits BAD-mediated death by inducing Ser-155 phosphorylation, which disrupts the PKA and ATP. As shown in Figure 6A (lane 2) , BAD interacted with BCL-X L in this assay as assessed by slot binding of BAD to prosurvival Bcl-2 proteins and thereby suppresses the ability of BAD to promote apoptosis.
blotting with anti-BAD antibodies. However, incubation of the BAD/BCL-X L complexes with PKA did not lead to displaced only a small amount of BAD from BCL-X L Ser-155 phosphorylation under conditions where PKA ( Figures 6C, lane 4) . In contrast, when the BCL-X L / did phosphorylate free BAD at Ser-155 (lane 2 of Figure  p136BAD complexes were coincubated with PKA and 6A, and Figure 1A) . These results support the structural 14-3-3, the reaction supernatants contained substandata indicating that the hydroxyl group of BAD Ser-155 tially more BAD immunoreactivity ( Figure 6C, lane 2) , faces toward the hydrophobic face of BCL-X L and is indicating that PKA enhances the release of BAD from therefore inaccessible to kinases when BAD is bound GST-BCL-X L when incubated in the presence of 14-3-3. to BCL-X L .
The ability of PKA to promote the release of BAD from Based upon the finding that Ser-136 phosphorylation BCL-X L depends on Ser-155 phosphorylation, as mutais necessary for Ser-155 phosphorylation in cells, we tion of Ser-155 to alanine abrogated the ability of PKA tested the hypothesis that BAD Ser-136 phosphorylation to induce enhanced BAD release into the supernatant induces a conformational change in the BAD/BCL-X L (Figure 6D, lanes 5 and 6) . Taken together, these findings complex that renders BAD Ser-155 accessible to kisuggest that phosphorylation of Ser-155 promotes the nases. BAD prephosphorylated at Ser-136 (p136BAD) dissociation of BAD from BCL-X L in a 14-3-3-dependent by Akt interacted as effectively as unphosphorylated manner. BAD with BCL-X L , suggesting that phosphorylation of Ser-136 alone does not induce a conformational change Discussion in BAD that causes BAD to dissociate from BCL-X L (Figure 6A, lane 3) . However, we found that phosphorylation A Model for BAD Inactivation of BAD Ser-136 also did not alter the BAD/BCL-X L com-This study identifies a mechanism by which survival plex in a manner that allows PKA to phosphorylate BAD signals inactivate the proapoptotic Bcl-2 family member at Ser-155 ( Figure 6A, lane 3) . This result indicates that BAD. In the absence of survival factors, BAD is dephosphosphorylation of BAD at Ser-136 alone does not renphorylated and tightly bound to prosurvival Bcl-2 family der BAD Ser-155 accessible to kinases when BAD is members such as BCL-X L at the outer mitochondrial bound to BCL-X L . membrane, where BAD initiates apoptosis by inhibiting We next tested the possibility that 14-3-3 binds to the BCL-X L function (Figure 7, stage 1) . BAD and BCL-X L BCL-X L /p136BAD complexes and induces a change in interact through an interface formed by the hydrophobic the complex that allows BAD to be phosphorylated at cleft of BCL-X L and the hydrophobic face of the amphi-Ser-155. Glutathione beads coupled to preassembled pathic BH3 domain of BAD. Upon treatment of cells with GST-BCL-X L /p136BAD complexes were incubated with survival stimuli, BAD becomes phosphorylated at Serrecombinant MBP-14-3-3⑀ protein, and then washed 136 (Figure 7, stage 2) . This phosphorylation site lies and subjected to a PKA kinase assay. As shown in Figure  outside of the BAD/BCL-X L interaction interface, and 6A (lane 5), incubation of GST-BCL-X L /p136BAD with phosphorylation of BAD at Ser-136 does not influence 100-fold molar excess of MBP-14-3-3 did not enhance the ability of BAD to bind to BCL-X L , suggesting that the ability of PKA to phosphorylate BAD at Ser-155. this phosphorylation event alone is not likely to inacti-However, we found that although 14-3-3 effectively vate BAD. Survival factor-mediated phosphorylation of bound to free p136BAD ( Figure 6B ), 14-3-3 did not stably BAD at Ser-136 subsequently recruits 14-3-3 proteins bind to the p136BAD/BCL-X L complexes ( Figure 6A, lane to the BAD/BCL-X L complex. However, 14-3-3 interacts 5). We therefore considered the possibility that 14-3-3 with phosphorylated ligands (such as phosphoBAD) weakly interacts with p136BAD/BCL-X L complexes, formwith dissociation constants ranging from 100 to 300 ing a transient ternary complex that increases the accessinmol (Yaffe et al., 1997), whereas BAD binds to BCL-X L bility of kinases to BAD Ser-155. To test this hypothesis, with a dissociation constant of 400 pmol, suggesting an in vitro kinase reaction was performed using PKA and that 14-3-3 binding likely does not substantially disrupt the p136BAD/BCL-X L complexes, both in the presence the BAD/BCL-X L complexes. Nevertheless, 14-3-3 proand the absence of MBP-14-3-3 proteins. We found teins effectively increase the accessibility of BAD to Serthat in the presence of 14-3-3 proteins, PKA was now 155 kinases, which then phosphorylate BAD within the capable of phosphorylating BAD at Ser-155 ( Figure 6A,  BAD BH3 domain. Phosphorylation of the BAD BH3 dolane 7) . The ability of 14-3-3 to enhance the accessibility main permanently blocks the ability of BAD to bind to of Ser-155 when BAD was in the BAD/BCL-X L complex BCL-X L due to electrostatic and steric constraints, thus required Ser-136 phosphorylation, as 14-3-3 proteins disrupting the interaction between BAD and BCL-X L (Figdid Figure 6D, lane 3) . These binds to 14-3-3 proteins and is localized to the cytoresults suggest that 14-3-3 proteins, through an unstaplasm (Figure 7, stage 4) . ble interaction with the BCL-X L /p136BAD complex, pro-Survival stimuli may induce the inactivation of proapomote the ability of Ser-155 kinases to phosphorylate ptotic BAD through multiple pathways. Neurotransmit-BAD Ser-155 when BAD is bound to BCL-X L .
ters activate PKA, which likely inactivates BAD by di-We next investigated whether the 14-3-3 and PKArectly or indirectly inducing the phosphorylation of BAD mediated phosphorylation of BAD at Ser-155 induced Ser-136 and by directly phosphorylating BAD at Serthe release of BAD from the BAD/BCL-X L complexes. 155. Growth factors, which activate Akt and in some GST-BCL-X L /p136BAD complexes were coincubated cases PKA, may induce BAD inactivation by a similar with PKA and/or 14-3-3, and the reaction supernatants mechanism in which Akt and/or PKA directly phosphorywere then isolated and analyzed for the presence of lates BAD at both Ser-136 and Ser-155. A fraction of released BAD by slot blotting. Incubation of 14-3-3 protein alone with the GST-BCL-X L /p136BAD complexes PKA, which is targeted to the mitochondria by AKAP proteins and has been shown to be important for BAD inactivate BAD by displacing BAD from BCL-X L . Consisphosphorylation, may be crucial for Ser-155 phosphorytent with this possibility, incubating BCL-X L /BAD comlation in this context . Alternatively, plexes with 100-fold molar excess of 14-3-3 protein ingrowth factors may principally regulate Ser-136 phosduced the dissociation of a small fraction of the BAD phorylation, which through 14-3-3 binding increases the bound to BCL-X L . However, this effect depends on high accessibility of Ser-155 to basally active kinases. The concentrations of 14-3-3 protein, as addition of equimomechanism and kinases by which growth factors induce lar amounts of 14-3-3 to BCL-X L /p136BAD complexes Ser-155 phosphorylation remain to be fully characdid not detectably induce the release of BAD from terized.
BCL-X L (data not shown). This failure of 14-3-3 to substantially disrupt the BAD/BCL-X L complexes is consistent with the measured affinity of the BAD BH3 domain Implications for Bcl-2 Family Regulation for BCL-X L being 100-to 1000-fold higher than the affinand for 14-3-3 Protein Function ity of phosphorylated BAD for 14-3-3. The ability of The observation that BAD is inactivated by phosphoryla-14-3-3 proteins to displace BAD from BCL-X L at the tion at Ser-155 has important implications for the underouter mitochondrial membrane may therefore not be standing of the regulation of Bcl-2 family members. sufficient to account for the growth factor-mediated in-Phosphorylation of BH3 domains may be a general activation of BAD. Consistent with this possibility, gemechanism by which trophic factors block the apoptotic netic data indicate than an additional event, Ser-155 activity of Bcl-2 family members. The proapoptotic Bcl-2 phosphorylation, is required for growth factors to block family member bNIP3 contains a consensus PKA phos-BAD-mediated death. The data presented in this study phorylation site (KKNS) at the residue homologous to support a role for 14-3-3 proteins in which they act to BAD Ser-155 within the bNIP BH3 domain. The Bcl-2 block BAD-mediated death by promoting the accumulafamily member BAX also contains an evolutionarily contion of BAD that is phosphorylated at Ser-155 and thereserved sequence within its BH3 domain that correfore incapable of binding to BCL-X L . Although there are sponds to a PKA phosphorylation site. It is possible that many possible means by which 14-3-3 may facilitate bNIP3 and BAX, like BAD, may be inactivated by survival BAD Ser-155 phosphorylation, one potential mechanism signals through phosphorylation within their BH3 dois that 14-3-3 may compete with BCL-X L for binding to mains. Consistent with this possibility, Akt and PKA BAD, thus liberating a small quantity of BAD from BCL-X L block BAX-mediated apoptosis (Kennedy et al., 1999;  and rendering this population of free BAD accessible to S. R. D. and M. E. G., unpublished data).
Ser-155 kinases. In order for 14-3-3 to promote BAD The findings presented in this paper also suggest an Ser-155 phosphorylation, the binding of 14-3-3 to BAD unappreciated role for 14-3-3 proteins in BAD inactivation. 14-3-3 proteins have been previously proposed to would have to induce the simultaneous dissociation of
